Compare BYND & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | EYPT |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 273.3M |
| IPO Year | 2018 | 2005 |
| Metric | BYND | EYPT |
|---|---|---|
| Price | $7.15 | $3.03 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $12.50 | ★ $25.91 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,496,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $967.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $3.05 |
| 52 Week High | $15.47 | $19.11 |
| Indicator | BYND | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 30.21 |
| Support Level | $0.63 | N/A |
| Resistance Level | $12.52 | $14.72 |
| Average True Range (ATR) | 0.39 | 0.21 |
| MACD | -0.23 | 0.15 |
| Stochastic Oscillator | 0.15 | 9.52 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.